Teladoc Health, Inc. insider Bliss Kelly reported an ownership change involving the company’s common stock on July 6, 2026, the same date the Form 4 was filed. The reported transaction covered 2,500 shares of Teladoc common stock at a price of $9.50 per share, representing a total transaction value of approximately $23,750. The filing notes that the transaction was carried out under a Rule 10b5-1 trading plan adopted by Kelly on August 14, 2025. Such plans allow company insiders to establish prearranged trading instructions at a time when they are not in possession of material nonpublic information, helping reduce concerns that later trades were timed around undisclosed corporate developments. The excerpt provided does not specify the transaction code, whether the transaction was an acquisition or disposition, the form of ownership, or Kelly’s beneficial ownership following the transaction. It also does not describe any related derivative securities, option exercises, vesting events, or equity award details. The Form 4 was signed on Kelly’s behalf by Adam C. Vandervoort, acting as attorney-in-fact. While the filing is limited in detail, it matters because Form 4 reports provide investors with timely visibility into insider transactions in Teladoc’s securities, particularly when trades occur under prearranged 10b5-1 plans.